New drug for stiff person syndrome granted designation to speed up development: ‘Thrilled for the community’

Kyverna Therapeutics’ new drug, KYV-101, has been designated by the U.S. Food and Drug Administration (FDA) a Regenerative Medicine Advanced Therapy (RMAT), the company announced on Monday. Read More in FOX News.   Read More in Red Pill NOWlej.